×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:PHAS

PhaseBio Pharmaceuticals Earnings Date, Estimates & Call Transcripts (2022)

$0.68
+0.03 (+4.62%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.65
$0.72
50-Day Range
$0.52
$1.39
52-Week Range
$0.50
$4.10
Volume
626,389 shs
Average Volume
474,408 shs
Market Capitalization
$33.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

Earnings Summary

Upcoming
Earnings Date
Aug. 11Estimated
Actual EPS
(May. 16)
-$0.23 Beat By $0.44
Consensus EPS
(May. 16)
-$0.67
Last Year's Q2 EPS
(5/13/2021)
-$0.87
Skip Charts & View Estimated and Actual Earnings Data

PHAS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PHAS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

PhaseBio Pharmaceuticals Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20221($0.50)($0.50)($0.50)
Q2 20221($0.79)($0.79)($0.79)
Q3 20221($0.74)($0.74)($0.74)
Q4 20221($0.83)($0.83)($0.83)
FY 20224($2.86)($2.86)($2.86)
Q1 20231($0.31)($0.31)($0.31)
Q2 20231($0.30)($0.30)($0.30)
Q3 20231($0.30)($0.30)($0.30)
Q4 20231($0.25)($0.25)($0.25)
FY 20234($1.16)($1.16)($1.16)

PHAS Earnings Date and Information

PhaseBio Pharmaceuticals last posted its earnings data on May 16th, 2022. The reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.44. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $5.83 million. PhaseBio Pharmaceuticals has generated ($2.39) earnings per share over the last year (($2.39) diluted earnings per share). Earnings for PhaseBio Pharmaceuticals are expected to grow in the coming year, from ($1.64) to ($1.25) per share. PhaseBio Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 11th, 2022 based off prior year's report dates.

PhaseBio Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/11/2022
(Estimated)
        
5/16/2022Q1 2022($0.67)($0.23)+$0.44($0.23)$5.83 million$0.12 million
3/24/2022Q4 2021($0.39)($0.90)($0.51)($0.90)$4.92 million$0.16 million
11/10/20219/30/2021($0.59)($0.66)($0.07)($0.66)$2.67 million$0.34 million
8/12/20216/30/2021($0.46)($0.60)($0.14)($0.60)$10.34 million
5/13/20213/31/2021($0.73)($0.87)($0.14)($0.87)
3/14/202112/31/2020($0.70)($1.03)($0.33)($1.03)
11/12/20209/30/2020($0.77)($0.86)($0.09)($0.86)  
8/11/2020Q2 2020($0.52)($0.98)($0.46)($0.98)
5/12/2020Q1 2020($0.4220)($0.52)($0.0980)($0.52)$0.38 million$0.32 million
3/30/202012/31/2019($0.40)($0.39)+$0.01($0.39)$0.40 million$0.76 million
11/14/2019Q3($0.36)($0.40)($0.04)($0.40)$0.35 million$0.24 million
8/13/2019Q2 2019($0.35)($0.330510)+$0.019490($0.33)$0.13 million$0.70 million
5/9/20193/31/2019($0.44)($0.30)+$0.14($0.30)$0.12 million$0.65 million
3/26/201912/31/2018($0.29)($0.26)+$0.03($0.26)$0.26 million
11/29/2018Q3($0.22)($10.45)($10.23)($10.45)$0.41 million












PhaseBio Pharmaceuticals Earnings - Frequently Asked Questions

When is PhaseBio Pharmaceuticals's earnings date?

PhaseBio Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 11th, 2022 based off last year's report dates. Learn more on PHAS's earnings history.

Did PhaseBio Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported ($0.23) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.67) by $0.44. Learn more on analysts' earnings estimate vs. PHAS's actual earnings.

How much revenue does PhaseBio Pharmaceuticals generate each year?

PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a recorded annual revenue of $10.83 million.

How much profit does PhaseBio Pharmaceuticals generate each year?

PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a recorded net income of -$131.07 million. PHAS has generated -$2.39 earnings per share over the last four quarters.

What is PhaseBio Pharmaceuticals's EPS forecast for next year?

PhaseBio Pharmaceuticals's earnings are expected to grow from ($1.64) per share to ($1.25) per share in the next year.

This page (NASDAQ:PHAS) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.